Latest news articles

Added 4 days ago Drug news

FDA approves Restylane Lyft as dermal filler for the back of the hands.- Galderma/Nestle.

The FDA has approved Restylane Lyft (hyaluronic acid), from Galderma/Nestle, dermal filler for the correction of age-related volume loss in...

Added 6 days ago Drug news

FDA issues a Complete Response Letter to Evolus for DWP 450 a proposed treatment for glabellar lines.

Evolus, Inc.has announced updates related to the regulatory progress of its pending Biologics License Application (“BLA”) for DWP 450 (prabotulinumtoxinA)...

Added 9 days ago Drug news

Phase III trial evaluating Dupixent in atopic dermatitis meets primary endpoint.- Regeneron.

A pivotal Phase III trial evaluating Dupixent (dupilumab), from Regeneron, to treat moderate-to-severe atopic dermatitis in adolescents (ages 12-17) met...

Search all news articles for Dermatology
 

 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Psoriasis

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

+ 2 more

Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria.

+ 7 more

IL-17A in Psoriasis

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress.

+ 1 more

Fabry Disease

Fabry Disease

Explore the pathophysiology and treatment options for Fabry disease, a deficiency of the lysosomal enzyme alpha-galactosidase A

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more

 

Guidelines

British Association of Dermatologists’ guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis, 2018

The overall objective of the guidelines is to provide up-todate, evidence-based recommendations on the investigation and management of secondary pruritus without underlying skin disorder and generalized pruritus of unknown origin (GPUO) in adults...

Added 2 months ago

British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017

The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for the management of pemphigus vulgaris (PV).

Added 2 months ago

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017

The overall aim of the guideline is to provide evidence-based recommendations on the use of biologic therapies (adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab) in adults, children and young people...

Added 8 years ago

Search all guidelines for Dermatology
 

Journal articles

Guselkumab: human monoclonal antibody against interleukin-23 for moderate to severe psoriasis.

Guselkumab is an antibody designed to bind to the p19 subunit of interleukin-23 (IL-23). Detailed studies of affected skin in patients with psoriasis demonstrated that guselkumab induced significant changes...

Added 2 days ago

Guselkumab for the treatment of moderate-to-severe plaque psoriasis.

Areas covered: This review outlines the pharmacologic properties, safety, and efficacy of guselkumab for the treatment of plaque psoriasis.

Added 2 days ago

Guselkumab for the treatment of psoriasis.

Psoriasis is a chronic immune mediated disease in which the interplay of T cells and keratinocytes seems to play a key role. In this context, the interleukin (IL)-23/IL-17 axis is currently considered to be crucial in the pathogenesis...

Added 2 days ago

Search all journal articles for Dermatology
 

Clinical trials

A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis

This is a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA)...

Added 1 year ago

Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects (HS rPMS)

The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.

Added 1 year ago

Search all clinical trials for Dermatology
 

Blog Posts

Hugh Harvey

Metrics Madness

Posted 2 years ago

You shouldn't judge a book by its cover. That much is true, but it's also common sense not to judge a book by measuring the whiteness of its pages, or the amount of hamsters you can place on it. So why do we measure the fabulous NHS with nonsense metrics?

CME

EAACI 2017: The future of urticaria – advances in CSU research

EAACI 2017: The future of urticaria – advances in CSU research
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE

Chronic Spontaneous Urticaria Case Consults: Changing Paradigms in the Age of Biologics

Chronic Spontaneous Urticaria Case Consults: Changing Paradigms in the Age of Biologics
Accrediting body
Credits available
0
Registration required
1
Subscription fee
FREE

Managing CSU and its comorbidities: from primary to secondary care

Managing CSU and its comorbidities: from primary to secondary care
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE
Search all CME for Dermatology